A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab

Multiple Myeloma Clinical Trial

Official title:

A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04302324
• Other study ID #: 19-12021155
• Status: Recruiting
• Phase: Phase 2
• Start date: October 28, 2021
• Est. completion date: January 2034

Study information

• Verified date: July 2023
• Source: Weill Medical College of Cornell University
• Contact: Kathleen P Research Nurse Coordinator, RN
• Phone: 646-962-6500
• Email: kap9111[@]med.cornell.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a single-center, non-randomized, phase 2 study in which patients will receive daratumumab (subcutaneous, SC) in combination with clarithromycin/pomalidomide/dexamethasone (D-ClaPd) until progressive disease (PD) or unacceptable toxicity. This study will test the hypothesis that in patients with previous daratumumab exposure, combination therapy of clarithromycin/pomalidomide/dexamethasone with daratumumab SC (D-ClaPd) will yield higher Very Good Partial Response (VGPR) rates in relapsed/refractory multiple myeloma patients than historical pomalidomide/dexamethasone treatment.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: January 2034
• Est. primary completion date: September 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Histologically confirmed Multiple Myeloma
• Relapsed and/or refractory myeloma defined as follows: Relapse or progressive disease after at least one previous line of therapy which must include prior daratumumab. At least 8 doses of daratumumab in a previous line must be administered either as monotherapy or in combination with a daratumumab-free interval of =3 months AND patient may be daratumumab refractory defined as less than a partial remission (PR) achieved on prior daratumumab-based therapy or have exhibited progression within 60 days of receiving daratumumab. If previous therapy was autologous stem cell transplant (SCT), over 3 months must have elapsed after SCT.
• Measurable disease as defined by > 0.5 g/dL serum monoclonal protein, >0.1 g/dL serum free light chains, >0.2 g/24 hrs urinary M-protein excretion, and/or measurable plasmacytoma(s).
• Females of childbearing potential(FCBP) must have a negative serum or urine pregnancy test within 10 - 14 days prior to and again within 24 hours of prescribing pomalidomide and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 4 weeks before she starts taking pomalidomide. FCBP must also agree to ongoing pregnancy testing.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.
• Able to take aspirin daily
• Life expectancy must be greater than 3 months.
• Be able to voluntarily sign and understand written informed consent.
• Absolute neutrophil count (ANC) =750 cells/mm3 (.75 x 109/L)
• Platelets count = 50,000/mm3 (50 x 109/L)
• Serum SGOT/AST = 2.0 x upper limits of normal
• Serum SGPT/ALT <3.0 x upper limits of normal
• Serum creatinine = 2.5 x upper limits of normal
• Serum total bilirubin = 1.5 x upper limits of normal (Total bilirubin = 1.5 x ULN is acceptable if bilirubin is fractionated and direct bilirubin <35%)
• All participants must be registered into the mandatory POMALYST REMS™ program and be willing and able to comply with the requirements of the POMALYST REMS™ program.

Exclusion Criteria:

• Prior exposure to non-daratumumab anti-CD38 monoclonal antibodies or pomalidomide. Prior pomalidomide exposure in 1 or more previous lines of therapy allowed if partial remission (PR) or better achieved. No disease progression may have occurred within 60 days of receiving pomalidomide.
• New York Heart Association (NYHA) Class III or IV heart failure, unstable cardiac arrhythmia, or unstable angina
• Myocardial infarction within the past 6 months
• Severe obstructive airway disease
• Planned high-dose chemotherapy and autologous stem cell transplantation within 6, 28-day treatment cycles after starting on treatment
• Female patients who are lactating or have a positive serum pregnancy test during the screening period
• Failure to have fully recovered (ie, = Grade 1 toxicity) from the reversible effects of prior chemotherapy
• Major surgery within 14 days before enrollment
• Radiotherapy within 14 days before enrollment (if area involved is small than within 7 days)
• Systemic treatment, within 14 days before the first dose, with strong CYP3A inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of Ginkgo biloba or St. John's wort
• Seropositive for human immunodeficiency virus (HIV), hepatitis B, and hepatitis C
• Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol
• Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
• Diagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease. Patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection
• Patient has greater than Grade 3 peripheral neuropathy, or Grade 2 pain
• Participation in other clinical trials within 30 days
• History of thromboembolic event within the past 6 months prior to enrollment

Related Conditions & MeSH terms

• Multiple Myeloma
• Neoplasms, Plasma Cell
• Refractory Multiple Myeloma
• Relapse Multiple Myeloma

Intervention

Drug:
• Daratumumab SC
Given as 1800mg via injection
• Clarithromycin
Given as 500mg oral capsule
• Pomalidomide
Given as 4mg oral capsule
• Dexamethasone
Given as 20mg IV and 20mg or 40mg oral tablets

Locations

Country	Name	City	State
United States	Weill Cornell Medicine - Multiple Myeloma Center	New York	New York

Sponsors (2)

Lead Sponsor	Collaborator
Weill Medical College of Cornell University	Janssen Scientific Affairs, LLC

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Very Good Partial Response Rate or better within 8 cycles of induction therapy	Very Good Partial Response or better defined as the proportion of participants with a documented Very Good Partial Response (VGPR) or better as best response per International Myeloma Working Group (IMWG) criteria, measured from date of enrollment through the end of the 8th induction cycle.	8 months
Secondary	Progression-Free Survival	Progression-Free Survival (PFS) is measured in months from the date of enrollment to the date of disease progression and/or death. Median estimate is calculated using the Kaplan-Meier methodology.	Approximately 3 years
Secondary	Overall Survival	Overall Survival (OS) is measured in months from the date of enrollment to the date of the participant's death. Greenwood's formula will be used to calculate 95% confidence intervals for the Kaplan-Meier survival estimates.	Approximately 5 years
Secondary	Complete Response Rate or Better	The proportion of participants with a documented Complete Response (CR) or better, per International Myeloma Working Group (IMWG) criteria.	Approximately 1 year
Secondary	Time to Progression	Measured in months between the date of enrollment and the first efficacy evaluation at which the participant has met the criteria for Progressive Disease	Approximately 3 years
Secondary	Time to Next Therapy	Measured in months from the date of enrollment to the start date of subsequent treatment for relapsed/refractory multiple myeloma	Approximately 3 years
Secondary	Duration of Response	Duration of Response (DoR) is defined as the time between the date of initial documentation of best response to the date of first documented evidence of disease progression.	Approximately 3 years
Secondary	Rate of minimal residual disease (MRD) negativity	Defined as a percentage of MRD negative participants	Approximately 8 months
Secondary	Rate of improvement in response during maintenance therapy	Percentage of patients that achieved an improved response during maintenance compared to end of induction.	Approximately 3 years
Secondary	Time to Best Response	Measured in months between the date of enrollment and the first efficacy evaluation at which the participant has met criteria for best response per International Myeloma Working Group (IMWG) criteria.	Approximately 8 months
Secondary	Overall Response Rate	The proportion of participants with a documented Overall Response (Partial Response or better), per International Myeloma Working Group (IMWG) criteria.	Approximately 1 year
Secondary	Very Good Partial Response (VGPR) Rate or better	The proportion of participants with a documented Very Good Partial Response (VGPR) Rate or better, per International Myeloma Working Group (IMWG) criteria.	Approximately 1 year